文献速递肝病消化内镜

非酒精性脂肪性肝病肝硬化中基于硬度与血小板无创预测食管静脉曲张

Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis.
PubMed 文献 · J Hepatol · 2018-05-24

这项多中心横断面研究在790例非酒精性脂肪性肝病(NAFLD)相关代偿期肝硬化患者中验证Baveno VI及扩展Baveno VI标准,并考虑M与XL探头肝硬度测量(LSM)差异。训练集314例中两标准分别减少33.3%和58%内镜检查,漏诊大食管静脉曲张分别为0.9%和3.8%;据此提出按探头区分的NAFLD肝硬化新标准,可使内镜筛查人数较两标准进一步绝对减少34.7%和10.5%,漏诊治疗需求静脉曲张风险低于5%。

要点

  • 训练集314例中Baveno VI标准减少33.3%内镜,漏诊大静脉曲张0.9%。
  • 训练集314例中扩展Baveno VI标准减少58%内镜,漏诊大静脉曲张3.8%。
  • 新NAFLD肝硬化标准:M探头血小板>110,000/mm3且LSM<30 kPa;XL探头血小板>110,000/mm3且LSM<25 kPa。

核心结论

  • 按FibroScan探头建立的新NAFLD肝硬化标准可使NAFLD肝硬化中筛查治疗需求静脉曲张的内镜使用减少一半以上,漏诊治疗需求静脉曲张的几率低于5%。
  • 在NAFLD相关代偿期肝硬化中,扩展Baveno VI标准在排除治疗需求静脉曲张方面优于Baveno VI标准,可避免不必要的侵入性筛查操作。
  • 所有无创评分标准在非肥胖患者中的准确性较低。

研究设计与样本

  • 多中心横断面研究,评估790例NAFLD相关代偿期肝硬化患者,均在可靠LSM后6个月内接受食管胃十二指肠镜(EGD)检查。
  • LSM由FibroScan®使用M和/或XL探头测量;314例同时用M和XL探头测量(训练集),338例仅用M探头、138例仅用XL探头测量(验证集)。
  • 优化标准的主要变量为节省内镜检查的百分比,同时将漏诊大治疗需求静脉曲张的风险保持在5%阈值以下。

主要发现

  • 训练集314例中,Baveno VI标准使EGD数量减少33.3%,漏诊大食管静脉曲张0.9%;扩展Baveno VI标准使EGD减少58%,漏诊大食管静脉曲张3.8%。
  • 排除治疗需求静脉曲张的最佳阈值:M探头为血小板计数>110,000/mm3且LSM<30 kPa,XL探头为血小板计数>110,000/mm3且LSM<25 kPa(NAFLD肝硬化标准)。
  • 使用NAFLD肝硬化标准较Baveno VI标准使接受EGD筛查的患者数量绝对减少34.7%,较扩展Baveno VI标准绝对减少10.5%。

关键数值与推荐

  • Baveno VI标准在训练集314例中减少EGD 33.3%,漏诊大食管静脉曲张0.9%。
  • 扩展Baveno VI标准在训练集314例中减少EGD 58%,漏诊大食管静脉曲张3.8%。
  • NAFLD肝硬化标准:M探头血小板计数>110,000/mm3且LSM<30 kPa;XL探头血小板计数>110,000/mm3且LSM<25 kPa。
  • NAFLD肝硬化标准较Baveno VI标准使EGD筛查人数绝对减少34.7%,较扩展Baveno VI标准绝对减少10.5%,漏诊治疗需求静脉曲张几率低于5%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Baveno VI and expanded Baveno VI criteria can avoid the need for esophagogastroduodenoscopy (EGD) to screen for varices needing treatment (VNT) in a substantial proportion of compensated patients with viral and/or alcoholic cirrhosis. This multicenter, cross-sectional study aims to validate these criteria in patients with compensated cirrhosis due to non-alcoholic fatty liver disease (NAFLD), accounting for possible differences in liver stiffness measurement (LSM) values between M and XL probes. METHODS: We assessed 790 patients with NAFLD-related compensated cirrhosis who had EGD within six months of a reliable LSM, measured by FibroScan® using M and/or XL probe. Baveno VI and expanded Baveno VI criteria were tested. The main variable used to optimize criteria was the percentage of endoscopies spared, keeping the risk of missing large VNT below a 5% threshold. RESULTS: LSM was measured by both M and XL probes (training set) in 314 patients, while only M or XL probe (validation sets) were used to measure LSM in 338 and 138 patients, respectively. In the training set, use of Baveno VI and expanded Baveno VI criteria reduced the number of EGD by 33.3% and by 58%, with 0.9% and 3.8% of large esophageal varices missed, respectively. The best thresholds to rule-out VNT were identified as platelet count >110,000/mm3 and LSM <30 kPa for M probe, and platelet count >110,000/mm3 and LSM <25 kPa for XL probe (NAFLD cirrhosis criteria). Thus, usage of NAFLD cirrhosis criteria would have led to an absolute reduction in the number of EGD screened patients of 34.7% and 10.5% with respect to Baveno VI and expanded Baveno VI criteria, respectively. CONCLUSION: The new NAFLD cirrhosis criteria, established for the FibroScan probe, can reduce the use of EGD for screening of VNT in NAFLD cirrhosis by more than half, with a chance of missing VNT below 5%. LAY SUMMARY: In non-alcoholic fatty liver disease-related compensated cirrhosis, the expanded Baveno VI criteria work better than the Baveno VI criteria for ruling out the presence of varices needing treatment, sparing unnecessary and invasive screening procedures. New diagnostic criteria for this patient group, based on liver stiffness measurement and platelet count, and optimized for the specific FibroScan® probe used, work better than both Baveno VI and expanded Baveno VI criteria. The accuracy of all non-invasive scoring criteria was lower in non-obese patients.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Petta S, Sebastiani G, Bugianesi E, et al. Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis. J Hepatol. 2018. PMID: 29802949. doi:10.1016/j.jhep.2018.05.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。